Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relationships between plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide.
Decensi A, Veronesi U, Miceli R, Johansson H, Mariani L, Camerini T, Di Mauro MG, Cavadini E, De Palo G, Costa A, Perloff M, Malone WF, Formelli F. Decensi A, et al. Among authors: de palo g. Clin Cancer Res. 2003 Oct 15;9(13):4722-9. Clin Cancer Res. 2003. PMID: 14581342 Clinical Trial.
Chemoprevention of breast cancer with fenretinide.
Veronesi U, De Palo G, Costa A, Formelli F, Decensi A. Veronesi U, et al. Among authors: de palo g. IARC Sci Publ. 1996;(136):87-94. IARC Sci Publ. 1996. PMID: 8791119 Review. No abstract available.
Chemoprevention of breast cancer: the Italian experience.
Decensi A, Bonanni B, Guerrieri-Gonzaga A, Torrisi R, Manetti L, Robertson C, De Palo G, Formelli F, Costa A, Veronesi U. Decensi A, et al. Among authors: de palo g. J Cell Biochem Suppl. 2000;34:84-96. doi: 10.1002/(sici)1097-4644(2000)77:34+<84::aid-jcb15>3.0.co;2-7. J Cell Biochem Suppl. 2000. PMID: 10762020 Review.
Chemoprevention of breast cancer with fenretinide.
Torrisi R, Decensi A, Formelli F, Camerini T, De Palo G. Torrisi R, et al. Among authors: de palo g. Drugs. 2001;61(7):909-18. doi: 10.2165/00003495-200161070-00002. Drugs. 2001. PMID: 11434448 Review.
Long-term effects of fenretinide, a retinoic acid derivative, on the insulin-like growth factor system in women with early breast cancer.
Decensi A, Johansson H, Miceli R, Mariani L, Camerini T, Cavadini E, Di Mauro MG, Barreca A, Gonzaga AG, Diani S, Sandri MT, De Palo G, Formelli F. Decensi A, et al. Among authors: de palo g. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1047-53. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11588130 Clinical Trial.
Effect of fenretinide on ovarian carcinoma occurrence.
De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, Veronesi U. De Palo G, et al. Gynecol Oncol. 2002 Jul;86(1):24-7. doi: 10.1006/gyno.2002.6663. Gynecol Oncol. 2002. PMID: 12079295 Clinical Trial.
Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.
Chiesa F, Tradati N, Grigolato R, Boracchi P, Biganzoli E, Crose N, Cavadini E, Formelli F, Costa L, Giardini R, Zurrida S, Costa A, De Palo G, Veronesi U. Chiesa F, et al. Among authors: de palo g. Int J Cancer. 2005 Jul 1;115(4):625-9. doi: 10.1002/ijc.20923. Int J Cancer. 2005. PMID: 15700313 Free article. Clinical Trial.
178 results